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Recruitment to ?time and target? in clinical gastroenterology studies 
Clinical gastroenterology research studies entered into the United Kingdom (UK) National Institute 
for Health Research (NIHR) portfolio are eligible for support provided by the UK Clinical Research 
Network (UKCRN).1 The overarching aim of the UKCRN is to maximise clinical research delivery by 
providing infra-structure support, which includes, for example, protected Clinician research time and 
Research Nurse support at individual study sites in NHS institutions. 
Individual study performance on the UKCRN PŽƌƚĨŽůŝŽ ŝƐ ĐůŽƐĞůǇŵŽŶŝƚŽƌĞĚ ƵƐŝŶŐ ƐĞǀĞƌĂů  ‘ŵĞƚƌŝĐƐ ?,
the principal one being study ƌĞĐƌƵŝƚŵĞŶƚ ƚŽ  ‘ƚŝŵĞ ĂŶĚ ƚĂƌŐĞƚ ? ?Each study is rated on a BRAG  ? 
black/red/amber/green system, with success (green) defined as greater than 80% recruitment 
ĂĐĐŽƌĚŝŶŐ ƚŽ ĞĂĐŚ ƐƚƵĚǇ ?Ɛ ƐĞůĨ-determined recruitment schedule.2 One can immediately see that 
funding bodies such as NIHR and the research Charities might be very interested in the number of 
 ‘ŐƌĞĞŶ ? ƐƚƵĚŝĞƐ ŝŶ ƚŚĞ 'ĂƐƚƌŽĞŶƚĞƌŽůŽŐǇPortfolio, as an indicator of the future ability of 
Gastroenterologists to deliver successful research projects, with which to make funding decisions. 
The same could be said of potential Pharma Trial Sponsors, which approach the UKCRN for 
identification of research sites for multi-centre studies.  
It is, therefore, in ƚŚĞ 'ĂƐƚƌŽĞŶƚĞƌŽůŽŐǇ ƌĞƐĞĂƌĐŚ ĐŽŵŵƵŶŝƚǇ ?Ɛ ďĞƐƚ ŝŶƚĞƌĞƐƚƐ ƚŽŵĂǆŝŵŝƐĞ ƚŚĞ
ŶƵŵďĞƌŽĨ ‘ŐƌĞĞŶ ?ƐƚƵĚŝĞƐŝŶƚŚĞWŽƌƚĨŽůŝŽ ?However, it appears that we are not currently performing 
very well (only 25% of open non-commercial studies were green compared with a Portfolio target of 
80% [data accessed 21/2/2014]). There are obviously many reasons why research projects do not 
proceed to plan and participant recruitment is lower than expected, which may be beyond the 
/ŶǀĞƐƚŝŐĂƚŽƌƐ ?ĐŽŶƚƌŽů ?However, there are ĂůƐŽƐĞǀĞƌĂů ‘/ŶǀĞƐƚŝŐĂƚŽƌ factors ? that probably contribute 
ƚŽ ƉŽŽƌ  ‘ŵĞƚƌŝĐ ? ƉĞƌĨŽƌŵĂŶĐĞ ĂŶĚ ƚŚĂƚ ĐĂŶ ďĞ ĂĚĚƌĞƐƐĞĚ ƌĞůĂƚŝǀĞůǇ ĞĂƐŝůǇ ďǇ 'ĂƐƚƌŽĞŶƚĞƌŽůŽŐǇ
researchers: 
1. Investigators should carefully consider and state a realistic, achievable sample size target for 
their study, along with an appropriate start date and study duration, during the Integrated 
Research Application System (IRAS) application process for study approvals. Targets set 
during the approvals process directly populate the Portfolio entry. One might expect that 
ďĂƐŝŶŐƚŚĞ ‘ƚŝŵĞĂŶĚƚĂƌŐĞƚ ?ŵĞƚƌŝĐŽn the predictions of the Investigator would give a study 
the best possible opportunity to ƌĞĐƌƵŝƚ ƚŽ  ‘ƚŝŵĞĂŶĚ ƚĂƌŐĞƚ ?. However, many Investigators 
still underestimate the time taken to gain regulatory approvals during study set-up and over-
estimate recruitment potential. Realistic targets compatible with the funding provided for a 
study are more likely to be achievable.     
2. Investigators should realise that if unexpected delays are encountered, the above targets set 
in the UKCRN Portfolio may be altered in the Portfolio, in agreement with the study funder. 
This can make a huge difference to an individual study BRAG rating. The key action is to 
inform Portfolio staff through the Gastroenterology team (see below), who can then help 
the Investigator gain the necessary evidence of a study extension with which to affect 
change in the Portfolio. 
3. Investigators need to update their study entry on the Portfolio on a regular basis. Portfolio 
data are updated every month and it is expected that each researcher will provide a monthly 
ƌĞĐƌƵŝƚŵĞŶƚ ĨŝŐƵƌĞ ? dŚŝƐ ŝƐ ? ŝŶ ĨĂĐƚ ? ĂŶŽƚŚĞƌ  ‘ŵĞƚƌŝĐ ?  ? so-ĐĂůůĞĚ  ‘recruitment upload 
ĞŶŐĂŐĞŵĞŶƚ ? or the % number of occasions when monthly accrual data are reported (one 
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which we are rather better at [95% in February 2014] ƚŚĂŶƌĞĐƌƵŝƚŵĞŶƚƚŽ ‘ƚŝŵĞĂŶĚƚĂƌŐĞƚ ?). 
One can easily imagine the effect of inaccurate recruitment data on individual study and 
overall Gastroenterology BRAG ratings. 
One factor which has hampered the ability of Investigators to fully engage with UKCRN Portfolio 
performance has been the lack of a simple means by which to communicate with Portfolio staff in 
the UKCRN Coordinating Centre.  Recently, this has changed with the appointment of a 60% FTE 
Gastroenterology Portfolio Co-ordinator, whose role is to ensure that individual non-commercial 
study data entries are as up-to-date and accurate as possible. We are convinced that the 
Gastroenterology BRAG rating will improve significantly if all Investigators respond in a timely and 
positive manner to requests from the Co-ordinator for information regarding individual studies that 
are supported by UKCRN infrastructure locally. The situation is slightly different regarding 
commercially sponsored studies, but the same strategy applies - maximal engagement with the 
h<ZE ŽŵŵĞƌĐŝĂů ƚĞĂŵ ǁŝůů ƌĞĂƉ ĚŝǀŝĚĞŶĚƐ ĨŽƌ ŝŵƉƌŽǀĞĚ  ‘ŵĞƚƌŝĐ ƉĞƌĨŽƌŵĂŶĐĞ ?. The 
Gastroenterology Portfolio Co-ordinator and Chair of the National Specialty Group can be contacted 
at gastro@nihr.ac.uk.  
The UKCRN has recently undergone re-configuration such that Gastroenterology research takes 
place in 15 Local Clinical Research Networks (LCRNs).3 Each LCRN has a Gastroenterology Lead, who 
is well-placed to help any Investigator communicate through the UKCRN Co-ordinating Centre to 
affect change in the Portfolio. If a Gastroenterologist is unclear who his or her regional Lead is, this 
can easily be determined by contacting the LCRN4 or British Society of Gastroenterology5. 
In summary, we believe that the above simple measures based around improved communication 
with the Gastroenterology Portfolio Coordinator and more realistic targets can improve individual 
ƐƚƵĚǇĂŶĚŽǀĞƌĂůů'ĂƐƚƌŽĞŶƚĞƌŽůŽŐǇZ'  ‘ŵĞƚƌŝĐƐ ?ǁŝƚŚĐŽŶƐĞƋƵĞŶƚďĞŶĞĨŝƚƐ ĨŽƌ Gastroenterology 
research in general by persuading funders of the feasibility of non-commercial  Gastroenterology 
studies and attracting more commercially-sponsored Gastroenterology research.   
Professor Mark Hull 
Chair, UKCRN National Gastroenterology Specialty Group and Yorkshire & Humber LCRN Lead for 
Gastroenterology 
Professor John McLaughlin 
Chair, BSG Research Committee and Greater Manchester LCRN Lead for Gastroenterology  
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